Acorda Therapeutics, Inc. ACOR 0.00 Acorda Therapeutics, Inc.

Home
⇒ 
Stock List ⇒ Acorda Therapeutics, Inc.
Range:0.6116-24.2Vol Avg:125680Last Div:0Changes:-0.21
Beta:1.46Cap:0.00BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Fri Feb 10 2006Empoloyees:102
CUSIP:00484M106CIK:0001008848ISIN:US00484M7002Country:US
CEO:Dr. Ron Cohen M.D.Website:https://www.acorda.com
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Stock Details

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection StatusPowered by StackThrow